Introduction: AKI and CKD {#s1}
=========================

Acute kidney injury (AKI) and chronic kidney disease (CKD) are the most severe consequences of kidney injury. AKI is commonly defined by a sudden (within 48 h) increase in serum creatinine and is usually transient ([@B1]). However, it may be as severe as to require renal replacement therapy and is associated with an increased risk of death. CKD is defined by abnormalities of kidney structure or function that persist for longer than three months and have consequences for health ([@B2]; [@B3]). CKD may progress to end-stage kidney disease requiring renal replacement therapy and is associated with an increased risk of premature death. Indeed, CKD was among the fastest growing causes of death worldwide and it is estimated that it will become the second most common cause of death within the next century in some countries ([@B4]). AKI and CKD are considered interconnected syndromes, as CKD predisposes to AKI and AKI may accelerate CKD progression ([@B5]). AKI was thought to be followed by complete recovery of kidney structure or function. However, the repair process may be unsuccessful leading to engagement of pathways promoting transition to CKD. In this regard AKI and CKD share a number of pathogenic processes, including inflammation and parenchymal cell death. Additionally, kidney injury during AKI may initiate or aggravate the processes of capillary rarefaction and fibrosis that characterize CKD ([@B7]; [@B6]; [@B8]). The clinical care of patients with AKI or CKD is marred by a paucity of effective therapeutic approaches. Thus, there is no therapy that prevents or accelerates recovery from AKI. Additionally, only a handful of drugs have been approved to slow the progression of CKD, including renin-angiotensin system blockers for proteinuric CKD and tolvaptan for polycystic kidney disease ([@B9]). However, they slow but do not completely prevent CKD progression and do not promote regression. Thus, novel therapeutic approaches should be developed based on an improved understanding of the cellular and molecular pathogenesis of AKI and CKD and of the drivers of the AKI-to-CKD transition.

Epigenetic Regulation of Gene Expression {#s2}
========================================

Epigenetic regulation refers to mechanisms that control gene expression without altering the nucleotide sequence. In general, epigenetic modifications are heritable during cell division although they are reversible and could be altered by age, disease, and environment. Epigenetic regulators include non-coding RNAs, and covalent modifications of histones and DNA. Histone modifications involve proteins responsible for the addition (writer), recognition (reader), and removal (eraser) of modifiers such as acyl-lysine modifications.

The main modification on DNA is methylation catalyzed by DNA methyltransferases (DNMTs). These are enzymes that methylate the 5-cytosine of CpG dinucleotides, frequently located in the first exons or near promoters ([@B10]). DNA promoter methylation is a silencing mechanism that inhibits transcription factor binding through chromatin packaging or repressor recruitment ([@B11]).

Histones are positively charged and they associate with negatively charged DNA to package in condensed chromatin and form nucleosomes, which are the basic units of chromatin. Nucleosomes pack 147 DNA base pairs around a histone octamer composed of two H3-H4 histone dimers stabilized as a tetramer which is flanked by two separate H2A-H2B dimers ([@B13]; [@B12]). Histone 1 (H1) acts as a linker and completes the chromatosome by protecting internucleosomal linker DNA ([@B14]). There are more than 100 types of histone modifications which regulate gene expression, such as methylation, acetylation, phosphorylation, crotonylation, sumoylation, and ubiquitination ([@B15]). However, the biological function of most of these modifications remains unknown. The best characterized consist of addition of acyl groups to specific amino acids, resulting in methylation, acetylation and crotonylation of lysine residues on histone H3.

Histone methylation requires the transfer of methyl groups to histone lysine or arginine residues by histone methyltransferases. Lysine residues can accept up to three methyl groups, resulting in mono-, di-, or trimethylated lysine, and arginine can accept up to two methyl groups, resulting in mono- or dimethylated arginine. Methyl groups can be removed by histone demethylases ([@B16]). The addition of methyl groups does not change histone charge, rather provides platforms for binding of transcription factors that may stimulate or suppress gene expression ([@B17]).

Histone acetylation, the transfer of an acetyl group to lysine residues, changes the charge of histones and favors chromatin relaxation, facilitating binding of transcription factors to promoters and gene expression ([@B18]). Histone acetylation is catalyzed by histone acetyltranferases (HAT) and it is reversible when histone deacetylases (HDAC) remove acetyl groups.

Histone lysine crotonylation (Kcr) was more recently described and consists in the transfer of crotonyl groups to lysine residues of histones, also conferring them negative charge ([@B19]). Recently, a role of histone Kcr was described in AKI ([@B20]). We now review the functional relevance of histone crotonylation in tissue physiopathology with emphasis in kidney disease and the implications for the development of novel therapeutic approaches.

Epigenetic Modifications in Renal Injury {#s3}
========================================

Both AKI and CKD are associated with cell death, inflammation, and diverse degrees of fibrosis. All of these could be regulated by epigenetic modifications. DNA methylation and histone acetylation and methylation are the most studied epigenetic mechanisms in renal injury, and evidence supports their functional relevance for kidney disease ([**Table 1**](#T1){ref-type="table"}).

###### 

Examples of changes in the overall pattern of DNA methylation or histone modifications during kidney disease.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Epigenetic modification                                                                                                  Overall levels in kidney                                                                                                                                                                                            Reference
  ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  **DNA methylation (-CH3):**                                                                                              **Overall increase in:** peripheral blood leukocytes from inflamed CKD G5 patientskidney in RASAL1 genes in mouse model of folic acid-induced fibrosiskidney in Klotho gene in mouse model of adenine-induced CKD   ([@B86]; [@B87]; [@B21])

  **Overall decrease in**:kidney in experimental AKI induced by IRIkidney in tubules of CKD patients                       ([@B88]; [@B23]; [@B89])                                                                                                                                                                                            

  **Histone methylation (Km, Rm, -CH3):**                                                                                  **Overall increase in:** kidney in experimental renal fibrosis induced by UUOkidney in diabetic nephropathy in uninephrectomy db/db mice                                                                            ([@B34]; [@B27]; [@B33])

  **Overall decrease in:** kidney in db/db micekidney in uninephrectomy C57BL/6 mice                                       ([@B34])                                                                                                                                                                                                            

  **Histone acetylation (Kac, -CO-CH3):**                                                                                  **Overall increase in:** kidney in experimental AKI-CKD transition induced by IRIkidney in experimental renal fibrosis induced by UUOkidney in diabetic nephropathy in uninephrectomy db/db mice                    ([@B34]; [@B36]; [@B33])

  **Overall decrease in:** kidney: early decrease in severe IRI AKI, and recovery during reperfusionkidney in db/db mice   ([@B35]; [@B34])                                                                                                                                                                                                    

  **Histone crotonylation (Kcr, -CO-CH=CH-CH3)**                                                                           **Overall increase in:** kidney in experimental nephrotoxic AKI by folic acid\                                                                                                                                      ([@B20]; [@B85])
                                                                                                                           **Changes in specific histones** peripheral blood mononuclear cells from IgA nephropathy patients: increased (HIST1H2AC, HIST1H4A, and decreased HIST1H1B)                                                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In parenthesis, modified amino acid (K, lysine; R, arginine) and the residue added.

AKI, acute kidney injury; CKD, chronic kidney disease; Kcr, crotonylation; IRI, ischemia-reperfusion injury; UUO, unilateral ureteral obstruction.

Global kidney DNA methylation was reduced in experimental AKI induced by ischemia-reperfusion injury (IRI) or cisplatin, and this was associated to the expression of inflammatory genes ([@B22]; [@B21]). In this regard, DNA methylation contributes to silencing the expression of the nephroprotective genes Klotho (which has anti-inflammatory and anti-fibrotic properties) and RASAL1 (which has anti-fibrotic properties) in AKI. DNMTs targeting by genetic ablation or pharmacological inhibition decreased fibrosis and prevented the AKI-to-CKD transition in part because of preserved expression of Klotho and RASAL1 ([@B23]; [@B24]; [@B25]).

Histone methylation, depending on context, lysine residue or extent of methylation may activate or repress gene transcription. Overall kidney histone methylation was increased in preclinical CKD induced by unilateral ureteral obstruction (UUO) or diabetic nephropathy \[reviewed in ([@B26])\]. In this regard, the expression of the histone methyl-transferase, EZH2, is increased in UUO and in CKD patients and its pharmacological inhibition reduced preclinical fibrosis ([@B27]). Similar results were found for the histone methyl-transferase, SMYD2 in clinical and preclinical PKD ([@B28]). In AKI induced by IRI or endotoxin, increased histone methylation has been linked to the increased expression of pro-inflammatory and pro-fibrotic genes ([@B29]; [@B30]). Moreover, histone methylation in the MCP1 and NGAL genes was detected in urine from AKI patients ([@B31]).

Histone acetylation generally favors gene expression and it has been extensively studied in renal injury. Global changes in kidney histone acetylation were observed in experimental AKI (e.g. IRI, endotoxemia) and CKD (UUO, diabetic nephropathy). Histone acetylation increased during renal injury in most animal models analyzed (endotoxemia, UUO, diabetic nephropathy in db/db mice) ([@B34]; [@B32]; [@B33]). During ischemia reperfusion injury (IRI), histone acetylation presents a more complex regulation, it is transiently decreased during ischemia, but it recovers, or even increases, after reperfusion, and may persist increased for 3 weeks ([@B35]; [@B36]). The impact of histone acetylation over the expression of specific relevant genes in AKI has been also studied, including the nephroprotective genes PGC1α and Klotho, 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) and the inflammatory cytokine Interleukine-6 (IL-6), among others ([@B37]; [@B38]; [@B39]). The functional contribution of histone acetylation to kidney injury is supported by numerous preclinical studies in AKI (e.g. cisplatin, IRI) and CKD \[e.g. UUO, polycystic kidney disease (PKD), diabetic nephropathy\] models, and HDAC inhibitors were frequently nephroprotective ([@B26]). Related with histone acetylation, another emergent line of research is the study of the bromodomain and extraterminal (BET) protein family. BET proteins are readers that bind to acetylated lysines of histones and facilitate binding of transcription factors. BET targeting has been beneficial in preclinical kidney disease and ongoing clinical trials of the BET inhibitor apabetalone explore kidney function as a secondary outcome ([@B40]; [@B26]).

These data show the complex regulation of epigenetic modifications in kidney diseases. The overall pattern of the different DNA and histone marks suggests that epigenetic modifications could favor the differential gene expression observed in kidney disease, opening the door for therapeutic strategies targeting epigenetic modulation.

Histone Crotonylation {#s4}
=====================

The application of high-sensitivity mass spectrometry techniques recently identified lysine crotonylation (Kcr) as a novel histone lysine acylation ([@B19]). Histone crotonylation represents an evolutionarily conserved histone mark which consists in the addition of a crotonyl group from crotonyl-coenzyme A to lysine residues, that similar to acetylation, modifies the charge of the histones ([@B19]; [@B26]). Nonetheless, the genomic pattern and function of histone crotonylation differs from histone acetylation ([@B19]). Histone crotonylation mainly marks active promoters and potential enhancers, but the impact on gene expression is unclear, as it can activate or repress gene transcription ([@B19]; [@B41]).

Histone Crotonyltranferases {#s4_1}
---------------------------

Histone crotonylation shares enzyme regulators with histone acetylation. Specifically, the histone acetyltransferase CBP/P300 provides the bulk of histone crotonyltransferase (HCT) (also termed histone crotonylase) activity in mammalian cells ([@B42]). The evolutionary conserved MOF, from the MYST family of histone acetyltransferases, also has HCT activity, as well as its yeast homologue (Esa1) ([@B43]; [@B42]). Additionally, similar to other lysine acylations, histone crotonylation has been proposed to occur non-enzymatically ([@B45]; [@B44]). The enzymatic activity of CBP/P300 over crotonylation or acetylation depends on the levels of the precursors acetyl-CoA and crotonyl-CoA. Since intracellular acetyl-CoA is more abundant that crotonyl-CoA, the rate of crotonylation is more sensitive to changes of precursor levels ([@B46]). In this line, while global histone acetylation is not affected by changes of sodium acetate availability, the levels of global histone crotonylation dramatically increase with increasing levels of sodium crotonate. This has physiological relevance, since crotonate addition also promotes gene expression *in vivo* and *in vitro* ([@B46]; [@B20]). Crotonate, the short-chain fatty acid (SCFA) precursor of crotonyl-CoA, is mainly produced by the colon microbiota ([@B47]). Circulating SCFA (acetate, crotonate, butyrate, and propionate) are taken up by tissues and converted into acyl-CoA by the acyl-CoA Synthetase Short Chain Family Member 2 (ACSS2) or eventually yield crotonyl-CoA through different metabolic pathways such as fatty acid β-oxidation ([@B46]; [@B48]) ([**Figure 1**](#f1){ref-type="fig"}). In this line, microbiota depletion decreases histone crotonylation in colon supporting the concept that microbiota may modulate epigenetic modifications ([@B41]). Additionally, intracellular acetyl-CoA, generated during glycolysis, may also influence the extent of histone crotonylation. Under conditions of acetyl-CoA depletion, caused either by low glucose levels or by glucose carbons being directed away from ATP citrate lyase (ACL), other acyl-CoAs, such as crotonyl-CoA, will face less competition for acyl-transferase activity and this could also lead to epigenetic changes ([@B44]).

![Histone crotonylation: enzymes and modulators. The gut microbiota is a source of short chain fatty acids (SCFAs) that inside cells may be metabolized to acetyl-CoA or crotonyl-CoA. These are the precursors that enzymes may use to promote lysine acetylation (Kac) or lysine crotonylation (Kcr) of histone and non-histone proteins. Crotonylated proteins have now been found within the nucleus and the cytoplasm. Already characterized crotonyltransferases (also termed crotonylases) include CBP/P300 and MOF, while histone decrotonylases include some histone deacetylases (HDAC) and sirtuin 3 (Sirt3). Kcr readers, proteins that identify Kcr in histones, include YEATS domain human proteins YEATS2 and AF9 as well as DPF family proteins MOZ and DPF2. Chromodomain Y-like (CDYL) negatively regulates histone crotonylation acting as a crotonyl-CoA hydratase that converts crotonyl-CoA required for Kcr into β-hydroxybutyryl-CoA. TCA, tricarboxylic acid; ACL, ATP citrate lyase; ACCS2, acyl-CoA Synthetase Short Chain Family Member 2.](fphar-11-00393-g001){#f1}

Kcr Readers {#s4_2}
-----------

Histone covalent modifications are recognized by chromatin-binding protein modules, so-called "readers". Acetyl lysine (Kac) residues are recognized mainly by bromodomains, YEATS domains, and double PHD-finger domains (DPF) ([@B42]). Bromodomains barely have affinity for long acyl modifications like Kcr sites ([@B49]), although TAF1 can recognize them with low affinity ([@B50]). By contrast, the evolutionarily conserved YEATS domain is a family of Kcr readers in yeast ([@B49]). Indeed, YEATS domain human proteins YEATS2 and AF9 have higher affinity for Kcr sites than for shorter acyl-groups such as acetyl ([@B52]; [@B51]). Likewise, DPF family proteins MOZ and DPF2 recognize a wide range of histone lysine acylations with a strong preference for Kcr ([@B53]).

Histone Decrotonylases {#s4_3}
----------------------

HDACs also have decrotonylase activity. In mammals, there are 11 metal-dependent HDACs divided into class I (HDACs 1--3, 8), class II (HDAC 4--7, 9, 10), and class IV (HDAC 11) and seven sirtuins (Sirt1-7) ([@B55]; [@B54]). Class I HDACs are the main histone decrotonylases ([@B56]). HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA, vorinostat) may enhance Kcr by inhibiting class I HDACs ([@B57]). The 3 µM vorinostat concentration used in these studies is within the range reached *in vivo* during the therapeutic use of the drug in humans (1.2 ± 0.62 µM) (<https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021991s002lbl.pdf>). HDAC1/2 containing complexes are critical regulators of histone Kcr ([@B58]). Thus, genetic deletion of HDAC1/2 reduced total decrotonylase activity by 85%. Differences from prior studies could be related to the analysis of cells ([@B58]) rather than of recombinant enzymes *in vitro* that described HDC3 decrotonylase activity ([@B19]; [@B59]), although there is the distinct possibility that different enzymes are more important in different cell types and environmental contexts. The histone decrotonylase activity of HDACs allows a further mechanism by which microbiota could increase crotonylation: generation of butyrate, an HDAC inhibitor ([@B60]). Although Sirt1 and Sirt3 have robust deacetylase activity ([@B61]), they can also catalyze the hydrolysis of lysine crotonylated histones, but only Sirt3 regulates Kcr dynamics and gene transcription in living cells ([@B62]).

Other Regulators of Kcr {#s4_4}
-----------------------

There are additional pathways that may regulate Kcr. Chromodomain Y-like (CDYL) negatively regulates histone crotonylation acting as a crotonyl-CoA hydratase that converts crotonyl-CoA required for Kcr into β-hydroxybutyryl-CoA.

Kcr vs Kac {#s4_5}
----------

Given the overlap between some Kcr and Kac sites in histones and shared modulators, initial concerns were raised as to the relevance of Kcr. It is now clear that Kcr and Kac are mechanistically and functionally different. Kcr is critically important for global transcription in mammalian cells ([@B63]). Specifically, in both human somatic and mouse male germ cell genomes, histone Kcr marks either active promoters or potential enhancers ([@B19]). Kcr but not Kac preferentially marked "escapee genes" during post-meiotic sex inactivation in mouse testis ([@B64]). Moreover, p300-catalyzed histone crotonylation directly stimulates transcription to a greater degree than histone acetylation ([@B46]). Furthermore, CBP/p300 mutants may be deficient in HAT activity but competent for HCT activity ([@B42]). Indeed, YEATS domains and DPF proteins showed a greater affinity for Kcr over Kac and by two different molecular mechanisms ([@B52]; [@B53]). Finally, Kcr are more resistant to deacetylases than Kac, offering a better chance to resist repression and enabling a robust and productive transcription ([@B65]).

Histone Crotonylation in Non-Renal Tissues {#s5}
==========================================

Histone crotonylation was initially well characterized in human somatic and male germ cells ([@B19]). Recently, histone crotonylation has been observed in different cells and tissues but its function over gene expression has been only explored outside the kidney in gametogenesis, reprogramming of pluripotent stem-cells and colon epithelial cells.

Gametogenesis and Pluripotent Stem Cells {#s5_1}
----------------------------------------

Histone crotonylation, but not acetylation, is a specific mark of active promoters or potential enhancers of sex chromosomes-linked genes in male haploid cells immediately following meiosis and is associated with the release of transcriptional repressors in such sex chromosomes, which is considered an important element in the programming of the genome in the postmeiotic phase of spermatogenesis ([@B19]; [@B64]). In this regard, CDYL decreased histone crotonylation and also sperm motility and fertility in mice ([@B66]). Histone crotonylation also favors the activation of pluripotency-inducing genes, maintenance of telomeres, and cell reprogramming during the chemical induction of pluripotent stem cells (CiPSCs) ([@B67]). In this line, in embryonic stem cells, Kcr and the expression of genes required for pluripotency were decreased by overexpression of mutant HDACs with impaired HDAC function but intact histone decrotonylase activity ([@B56]).

Gut Cells {#s5_2}
---------

In colon epithelial cells, crotonylated histones, more concretely H3K18cr, was associated to transcription start sites of genes involved in cancer, suggesting that deregulation of histones crotonylation may be linked to cancer. Butyrate from gut microbiota inhibited HDACs with decrotonylase activity, thus modifying the level of gut histone crotonylation and linking the gut microbiota with local tissue histone crotonylation ([@B41]). In addition, microbiota depletion resulted in increased expression of HDAC2 ([@B41]), an enzyme with decrotonylase activity and also related to tumorigenesis in colon cancer ([@B68]) and with the progression from adenoma to carcinoma ([@B69]). Several cancer-associated proteins are subject to Kcr by CBP/p300 ([@B70]). On the other hand, HDAC inhibitors induce the intestinal mucosa expression of ACSS2, which favors latent HIV reactivation through histone crotonylation ([@B71]).

Lysine Crotonylation Beyond Histones {#s6}
====================================

Kcr has been identified in non-histone proteins. Studies using specific antibody enrichment followed by high resolution mass spectrometry and intensive bioinformatics analysis have demonstrated that Kcr occurs in a large number of proteins, predominantly in nuclei, but also in the cytoplasm ([@B63]; [@B57]; [@B72]). Crotonylation was promoted by exposure to crotonate or CBP/p300 overexpression ([@B63]). Crotonylated non-histone proteins have been characterized in different cell types such as Hela cells, H1299 cells ([@B63]; [@B72]), HTC 116 ([@B70]), and in tissues such as lung, kidney, liver, colon, uterus, ovary, and brain of mice ([@B73]; [@B72]).

Crotonylation of non-histone proteins is thought to be important in various biological processes, such as RNA splicing, gene expression, chromatin organization, nucleic acid metabolism, and the cell cycle ([@B63]). However, the requirement of crotonylation for most of these putative cellular functions has not been formally tested. HDAC1 is among the crotonylated non-histone proteins in HELA cells treated with crotonate and HDAC1 crotonylation leads to a reduced deacetylase activity ([@B63]).

Histone Crotonylation in Kidney Injury {#s7}
======================================

Kidney injury is probably the best characterized disease condition so far in terms of extent and function of histone crotonylation ([@B74]) ([**Figure 2**](#f2){ref-type="fig"}). Histone Kcr was observed in tubular cells from healthy mouse and human kidney and nephrotoxic AKI was associated with a global increase in kidney histone crotonylation ([@B20]). Likewise, in cultured proximal tubule epithelial cell cultures, stimulation with the proinflammatory cytokine TWEAK, a driver of kidney injury ([@B75]; [@B76]), increased global histone Kcr ([@B20]). Additionally, crotonate supplementation increased global histone Kcr in cultured tubular cells and in the kidneys *in vivo*. Thus, levels of histone crotonylation in kidney tubular cells may be modified by cell stress or by crotonate administration.

![Role of histone crotonylation in acute kidney injury (AKI). The figures depict the different stages of kidney injury and the integration of spontaneous histone crotonylation or therapeutic drug-induced histone crotonylation. **(A)** Triggers of kidney injury, such as diverse forms of cell stress, including the proinflammatory cytokine TWEAK, cause lethal or sublethal (e.g. decreased expression of the master regulator of mitochondrial biogenesis PGC1α or sirtuin 3, Sirt3) kidney cell injury and elicit a proinflammatory response (e.g. chemokine synthesis) ([@B78]; [@B91]; [@B77]). **(B)** This will induce kidney injury that may be magnified by recruitment of inflammatory cells ([@B3]). **(C)** During AKI, global kidney histone crotonylation increases and this may be further increased by treatment with crotonate ([@B20]). Decreased expression of decrotonylases, such as Sirt3 may contribute to increased global histone crotonylation. Based on crotonate therapy results, we hypothesize that the overall impact of increased global histone crotonylation supposes a brake in the kidney injury process, and, thus, a beneficial adaptive process. **(D)** As already indicated, treatment with crotonate improves kidney injury and restores PGC1α or Sirt3 expression, decreasing chemokine production. Based on new knowledge of the therapeutic effects of HDAC inhibitors on kidney injury *in vivo* and in culture ([@B84]; [@B83]), we now hypothesize that part of this beneficial effect of HDAC inhibitors may be related to their role in crotonylation regulation, rather than or in addition to inhibition of deacetylase activity. **(E)** Eventually, either spontaneously or following acceleration of recovery by therapy, kidney function recovers.](fphar-11-00393-g002){#f2}

The increased histone crotonylation in cells stimulated with TWEAK and in AKI kidneys was associated with decreased PGC1α and Sirt-3 expression and with increased CCL2 expression, a chemokine which contributes to kidney inflammation ([@B20]). PGC1α and Sirt-3 have nephroprotective actions ([@B79]; [@B78]; [@B77]). Besides, Sirt3 and PGC1α regulate each other. PGC1α is a transcription factor and a major regulator of gluconeogenesis, as well as driver of mitochondrial biogenesis, and Sirt3 is a mediator of the effect of PGC1α on mitochondrial biogenesis ([@B80]). The increased histone crotonylation induced by crotonate administration in mice and in cultured tubular kidney cells resulted in an increased PGC1α and sirtuin-3 expression, as well as a decrease of CCL2 expression. That is, the systemic administration of crotonate prevents the decrease of PGC1α and sirtuin-3 expression, and the increase of CCL2 expression in mice with AKI and this was associated to protection from experimental nephrotoxic AKI and preservation of renal function ([@B74]). Taken together, the cell culture evidence that crotonate increased histone crotonylation and prevented proinflammatory responses while preserving nephroprotective gene expression, the fact that it had similar actions *in vivo* in AKI and that it protected from AKI, suggests that crotonate may have a potential therapeutic effect on kidney damage, and more specifically in AKI, by increasing histone crotonylation. If this hypothesis is correct, then the spontaneous global increase in histone crotonylation during AKI may be considered part of an adaptive mechanism, even allowing for potential discrepant level of crotonylation in specific genes. In this regard, the previously described beneficial effects of HDAC inhibitors such as valproic acid or trichostatin, in kidney damage ([@B82]; [@B81]), should be viewed in the context of their potential to induce histone crotonylation ([@B59]; [@B56]; [@B58]) and not just through the light of their impact on histone lysine acetylation. Some examples of beneficial effects of HDAC inhibitors that have been ascribed to modulation of histone acetylation but may in fact be related to increase histone crotonylation include preservation of the expression of the antiaging and nephroprotective gene Klotho despite the presence of Klotho suppressors such as inflammatory cytokines and albuminuria, and similar results were observed with PGC1α expression ([@B84]; [@B83]; [@B77]). This hypothesis should be addressed through specifically designed experiments.

In peripheral blood mononuclear cells from dialysis patients or healthy subjects, liquid chromatography--mass spectrometry identified 347 crotonylated proteins ([@B85]). A total of 345 proteins were differentially expressed between hemodialysis patients and controls, 93 of them upregulated and 252 downregulated. However, functional enrichment analysis did not show significant differences between upregulated and downregulated proteins and no direct relation was observed between Kcr ratio and levels of expression.

Summary and Future Perspectives {#s8}
===============================

In summary, histone lysine crotonylation is a recently described posttranslational histone modification which, like previously described ones, has the potential to regulated gene expression. To date, its function in disease has been more extensively investigated in kidney injury. AKI and tubular cell stress in culture are characterized by increased global histone crotonylation. While it is conceivable that this is the end-result of differential crotonylation of many different genes, with very different impact on the expression of these genes, supplementing crotonate both increased kidney histone crotonylation and was nephroprotective and this was associated with potential beneficial changes in the expression of nephroprotective and proinflammatory genes. This opens the door to explore therapeutic strategies based on the modulation of histone crotonylation that, besides supplementing crotonate, may also include modulation of the microbiota and the use of HDAC inhibitors. In this regard the literature on the nephroprotective effects of HDAC inhibition should be re-examined from the point of view of their potential regulation of histone crotonylation. A detailed exploration of the role of histone crotonylation in kidney disease may facilitate the study of its impact in health and disease of other organs. Finally, the regulation and role of non-histone crotonylation remains essentially unexplored. A recent manuscript using a proteomics approach identified 155 upregulated and 198 downregulated crotonylated proteins in peripheral blood mononuclear cells from IgA nephropathy patients, of which only three were histones. Since only six patients were studied, whether these changes are linked to IgA nephropathy itself, to CKD or to other factors, remains unclear ([@B86]). In any case, this manuscript identifies the potential of a systems biology approach and eventual bioinformatics and machine learning analyses in advancing the field. Thus, a systems biology analysis of the impact of HDAC inhibitors in AKI may identify new biomarkers or therapeutic targets.
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